MetLife, Inc.

NYSE:MET Aktierapport

Börsvärde: US$53.1b

MetLife Framtida tillväxt

Future kriterier kontrolleras 1/6

MetLife förväntas öka intäkter och intäkter med 13.8% respektive 4.3% per år. EPS förväntas tillväxt med 17.2% per år. Avkastningen på eget kapital förväntas bli 16% om 3 år.

Viktig information

13.8%

Tillväxttakt i vinsten

17.17%

Tillväxttakt för EPS

Insurance vinsttillväxt2.0%
Intäkternas tillväxttakt4.3%
Framtida avkastning på eget kapital16.04%
Bevakning av analytiker

Good

Senast uppdaterad21 May 2026

Senaste uppdateringarna om framtida tillväxt

Recent updates

Uppdatering av berättelse • May 03

MET: Share Repurchases And Dividend Increases Will Support Future Upside Potential

Analysts have slightly adjusted their fair value estimate for MetLife, nudging the implied price target from about $89.06 to $89.31. This reflects modest tweaks to assumptions around the discount rate, long term revenue growth, profit margin and future P/E multiples.
Seeking Alpha • Apr 26

MetLife: A Great Time To Buy The Preferred Stock

Summary MetLife preferred shares now yield over 6% as rising rates pressure prices, offering attractive risk/reward for long-term investors. MET's preferred dividends are well covered, with payout ratios under 4% of adjusted earnings and likely dropping to 3% as EPS grows. Series F preferred, MET.PR.F, trades at ~$19.25 for a 6.15% yield. Low payout ratio and strong balance sheet support continued payments. Double-digit adjusted EPS growth and 15–17% ROE guidance suggest MET common shares also offer compelling upside below $80/share. Read the full article on Seeking Alpha
Uppdatering av berättelse • Apr 17

MET: Share Repurchases Following Index Exit Will Support Future Upside Potential

Analysts have slightly reduced their MetLife fair value estimate to $89.06 from $90.50, reflecting minor adjustments to assumptions for the discount rate, revenue growth, profit margin, and future P/E ratio that refine their outlook for the shares. What's in the News MetLife has been dropped from the S&P 100 index, which may influence how some index funds and benchmarks gain exposure to the stock (Key Developments).
Uppdatering av berättelse • Apr 01

MET: Share Repurchases And Index Exit Will Shape Future Upside Potential

Analysts have trimmed their average MetLife price target slightly to $90.50 from $90.73, citing updated views on revenue growth, profit margins, and future P/E assumptions. What's in the News MetLife, Inc.
Uppdatering av berättelse • Mar 18

MET: Share Repurchases Will Support Future Upside Potential

Analysts have slightly adjusted their price target for MetLife to $90.73 from $90.93, reflecting updated views on discount rates, revenue growth, profit margins, and future price-to-earnings (P/E) assumptions. What's in the News MetLife reported that from October 1, 2025 to January 31, 2026 it repurchased 7,608,263 shares, representing 1.15% of shares, for a total of US$600 million under its current buyback program (Key Developments).
Uppdatering av berättelse • Mar 04

MET: Buybacks And Retirement Income Agreements Will Drive Future Upside

Analysts have trimmed their price target on MetLife to about $90.93 from roughly $92.93. This reflects updated views on slightly lower expected revenue growth, a modestly softer profit margin, a higher discount rate, and a largely unchanged future P/E assumption.
Uppdatering av berättelse • Dec 16

MET: Retirement Income Agreements Will Drive Future Upside In Earnings Power

Analysts have marginally reduced their price target on MetLife to approximately 92.93 dollars from 93 dollars, citing a slightly higher assumed discount rate. This more than offsets modest improvements in forecast profit margins and valuation multiples.
Uppdatering av berättelse • Nov 07

MET: Revenue Will Advance On New Retirement Income And Employee Support Agreements

Analysts have slightly reduced their price target for MetLife from $93.33 to $93.00, reflecting minor adjustments to discount rate and profit margin assumptions. They maintain a positive outlook on revenue growth.
Uppdatering av berättelse • Oct 24

Digital Expansion And Employee Support Benefits Will Drive Outperformance Ahead

Analysts have modestly raised their price target for MetLife, increasing it from $93.00 to $93.33 per share. They cited slight improvements in projected revenue growth and profit margins as the reason for the adjustment.
Uppdatering av berättelse • Oct 09

International Demand And Digital Transformation Will Fuel Success

Analysts have raised their fair value estimate for MetLife from $91.86 to $93.00. This reflects slight adjustments to discount rates and growth assumptions.
Uppdatering av berättelse • Sep 04

International Demand And Digital Transformation Will Fuel Success

With no change in revenue growth forecasts or discount rate, MetLife’s fair value estimate remains steady at $91.86. What's in the News MetLife will redeem all outstanding shares of its 3.850% Fixed Rate Reset Non-Cumulative Preferred Stock, Series G, at $1,000 per share; dividends of $19.250 per share will be paid separately, and all further dividends cease post-redemption.
Analysartikel • Jun 11

It's Unlikely That MetLife, Inc.'s (NYSE:MET) CEO Will See A Huge Pay Rise This Year

Key Insights MetLife's Annual General Meeting to take place on 17th of June Salary of US$1.50m is part of CEO Michel...
Seeking Alpha • Feb 11

MetLife: Double-Digit EPS Growth With A Single-Digit P/E, Strong Chart

Summary MetLife, Inc. is rated a buy due to its solid value, above-market dividend yield, and favorable technical chart despite recent earnings misses. Insurance stocks, including MET, have lagged behind the Financials sector and S&P 500, with premium increases expected to slow as consumers react to rising costs. MET's 2025 outlook is positive, with analysts forecasting over 17% EPS growth and 5%-6% revenue growth, despite recent underperformance in certain segments. Key risks include lower stock prices, falling interest rates, and regulatory challenges, but MET's strong investment income and share buybacks are positive factors. Read the full article on Seeking Alpha
Seeking Alpha • Nov 26

MetLife Upgraded To Buy As Financials And Insurance Show Further Upside Potential

Summary MetLife stock gets upgraded to a buy, from my prior hold rating, as indicators point to further share price potential in the financials sector, as well as the insurance subsector. Data points to future continued demand for annuities and life insurance, and MetLife has in Q3 achieved new organic customer growth in 2 key businesses. Although its dividend yield is not stellar vs. peers, it has a 10-year track record of proven dividend growth, something it has potential to continue. Even though it is trading at a 10-year high, it remains undervalued on P/E and EV/EBITDA vs. peers, so continues to present a buy opportunity. Read the full article on Seeking Alpha
Seeking Alpha • Sep 23

MetLife: One Of The Best Life Insurance Stocks

Summary MetLife's strong financial performance, with a 17.5% increase in adjusted EPS and a 15.2% rise in book value, makes it an attractive investment. Despite comparable performance to Aflac, MetLife's lower valuation offers better value for shareholders. MetLife's growing dividend yield and robust share buyback program enhance shareholder value, with ample cash reserves supporting future buybacks. Risks include potential commercial real estate portfolio defaults and market volatility, but MetLife's strong fundamentals and attractive valuation make it a compelling choice. Read the full article on Seeking Alpha
Seeking Alpha • Jul 09

Higher For Longer? Consider MetLife's Preferred Shares With A 6.6% Yield

Summary MetLife's preferred shares, particularly the Series A with floating dividends, offer potential for investors in a 'higher for longer' inflation and interest rate environment. MetLife's strong financial performance in Q1 2021, with net profit covering preferred dividends by less than 8%. Series A preferred shares have a minimum 4% floor for dividends, with potential for higher yields based on 3 month SOFR rate adjustments. Read the full article on Seeking Alpha
Seeking Alpha • Jun 26

MetLife Looks Like An Undervalued Property In An Unpopular Neighborhood

Summary MetLife shares have outperformed peers, but life insurance stocks have not really been in favor given concerns about CRE losses and rate cuts. Higher rates have allowed MetLife to reprice its investment portfolio at higher rates and sell more spread products, and the benefits will last even as rates fall. There are understandable concerns about MetLife's CRE exposure (office in particular), as the insurer is overweight here, but losses will take years to materialize and can be absorbed. MetLife's focus on profitable core businesses like group life and health, pension risk transfer, and international markets should lead to steady growth and returns for investors. This is something of a contrarian call given weak sector sentiment, but MetLife's differentiated model and ability to out-earn its cost of equity should drive outperformance. Read the full article on Seeking Alpha
Seeking Alpha • Apr 18

MetLife: Healthy But Lacks Clear Advantages

Summary MetLife has experienced a decade of light shrinking instead of growth. This started as early as 2015 and was attributed to increased competition and a decrease in annuity sales, but this never seemed to improve. With their current size, competitive hurdles, and lack of clear targets for growth internationally, shares of MET will likely only give mediocre returns at best. Read the full article on Seeking Alpha

Prognoser för vinst- och omsättningstillväxt

NYSE:MET - Analytikernas framtida uppskattningar och tidigare finansiella data (USD Millions )
DatumIntäkterIntäkterFritt kassaflödeKassaflöde från rörelsenGenomsnittligt Antal analytiker
12/31/202887,2256,647N/AN/A6
12/31/202783,3036,2674,800N/A9
12/31/202679,2615,6554,600N/A7
3/31/202677,5843,43415,51715,517N/A
12/31/202577,0793,17317,09217,092N/A
9/30/202571,9323,63414,62714,627N/A
6/30/202573,0114,09115,22915,229N/A
3/31/202573,4944,30516,53216,532N/A
12/31/202470,9824,22614,59814,598N/A
9/30/202471,3403,56115,16915,169N/A
6/30/202468,7672,70814,47514,475N/A
3/31/202467,5702,16614,02314,023N/A
12/31/202366,9011,38013,72113,721N/A
9/30/202363,4792,35510,84010,840N/A
6/30/202369,8963,03111,67511,675N/A
3/31/202368,7473,54213,03013,030N/A
12/31/202268,7645,09913,04413,044N/A
9/30/202273,2514,72616,08316,083N/A
6/30/202267,8735,14915,27915,279N/A
3/31/202270,9237,63413,14013,140N/A
12/31/202168,6886,65412,34712,347N/A
9/30/202170,4095,30112,40912,409N/A
6/30/202169,5194,41312,69612,696N/A
3/31/202165,0941,11511,28811,288N/A
12/31/202067,8425,19111,63911,639N/A
9/30/202065,5675,60311,66711,667N/A
6/30/202068,2307,12212,02012,020N/A
3/31/202071,6288,73813,56113,561N/A
12/31/201969,6205,721N/A13,786N/A
9/30/201968,1397,195N/A9,906N/A
6/30/201965,7505,923N/A9,293N/A
3/31/201969,4385,084N/A12,514N/A
12/31/201867,9414,982N/A11,738N/A
9/30/201868,1125,244N/A12,487N/A
6/30/201867,9805,235N/A13,688N/A
3/31/201862,1195,197N/A11,481N/A
12/31/201762,3084,893N/A12,283N/A
9/30/201759,2631,893N/A15,876N/A
6/30/201758,9082,044N/A14,069N/A
3/31/201757,2632,229N/A14,959N/A
12/31/201660,7323,481N/A14,774N/A
9/30/201665,2094,994N/A13,733N/A
6/30/201667,2555,169N/A13,445N/A
3/31/201669,9525,219N/A13,356N/A
12/31/201561,2573,891N/A14,052N/A
9/30/201571,8885,857N/A14,953N/A
6/30/201572,6776,724N/A16,343N/A

Analytiker Framtid Tillväxt Prognoser

Intäkter kontra sparande: MET s prognostiserade vinsttillväxt ( 13.8% per år) är över sparkvoten ( 3.5% ).

Resultat vs marknad: MET s intäkter ( 13.8% per år) förväntas växa långsammare än marknaden för US ( 16.7% per år).

Höga tillväxtresultat: MET s intäkter förväntas växa, men inte avsevärt.

Intäkt vs marknad: MET s intäkter ( 4.3% per år) förväntas växa långsammare än marknaden för US ( 11.7% per år).

Hög tillväxtintäkter: MET s intäkter ( 4.3% per år) förväntas växa långsammare än 20% per år.

Tillväxtprognoser för vinst per aktie

Framtida avkastning på eget kapital

Framtida ROE: MET s avkastning på eget kapital förväntas bli låg om 3 år ( 16 %).

Upptäck tillväxtföretag

7D

1Y

7D

1Y

7D

1Y

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/05/21 16:05
Aktiekurs vid dagens slut2026/05/21 00:00
Intäkter2026/03/31
Årlig intjäning2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

MetLife, Inc. bevakas av 32 analytiker. 9 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Jacob KilsteinArgus Research Company
Jay GelbBarclays
Taylor ScottBarclays